Newamsterdam pharma to present at the 24th annual needham virtual healthcare conference

Naarden, the netherlands and miami, march 31, 2025 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams or “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that ian somaiya, chief financial officer of newamsterdam pharma, will participate in a virtual fireside chat at the 24th annual needham virtual healthcare conference on monday, april 7, 2025 at 12:45 p.m. et.
NAMS Ratings Summary
NAMS Quant Ranking